{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:44:08Z","timestamp":1781534648544,"version":"3.54.5"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Theater Army 2023 Medical Autonomous Research Project","award":["2023LC09"],"award-info":[{"award-number":["2023LC09"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause for chronic liver diseases around the globe, disproportionately affecting aging populations. This research focused on the global burden of NAFLD in adults aged 45 and older from 1990 to 2021, with projections extending to 2035.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from the Global Burden of Disease (GBD) Study between 1990 and 2021, we assessed the incidence, prevalence, mortality and disability-adjusted life years (DALYs) related to NAFLD in adults aged 45 and older in 204 countries and territories. To evaluate the underlying drivers including demographics and lifestyle, Bayesian age-period-cohort (BAPC) modeling was employed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2021, the worldwide prevalence of NAFLD has reached 48.35 million cases (with a 95% uncertainty interval of 44.23 to 52.36 million). Among individuals aged\u2009\u2265\u200945 years, age-standardized incidence rose by 18.3% (EAPC\u2009=\u20090.53) from 1990 to 2021, while prevalence increased by 24.5% (EAPC\u2009=\u20090.74). Mortality and DALYs also climbed, with Egypt, Mongolia, and Andean Latin America bearing the highest burdens. A bell-shaped Socio-Demographic Index (SDI) correlation emerged, peaking in medium-SDI regions (e.g., North Africa, Middle East). Projections indicate persistent female predominance, with ASIR expected to rise to 826.11 (women) vs. 665.72 (men) per 100,000 by 2035.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis explored the global burden of NAFLD in people aged 45 years and older from 1990 to 2021, demonstrating significant epidemiological changes. Age-standardized incidence and prevalence rates rose by 18.3% and 24.5%, respectively, with the most pronounced burden observed in middle-to-high SDI regions attributable to aging populations. Although women exhibited higher incidence rates, mortality rates remained consistently elevated among men, underscoring unmet intervention needs. Projections to 2035 indicate increasing incidence (particularly in women) alongside moderate declines in mortality and DALYs, underlining the requirement for prevention strategies that are specific to age and gender.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0342697","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:22:31Z","timestamp":1772648551000},"page":"e0342697","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Global, regional, and national burden of nonalcoholic fatty liver disease among adults aged \u2265 45 years: A comprehensive analysis of epidemiological trends and projections to 2035"],"prefix":"10.1371","volume":"21","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieru","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7057-1357","authenticated-orcid":true,"given":"Chenyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"1","key":"pone.0342697.ref001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"pone.0342697.ref002","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"pone.0342697.ref003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"C Estes","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"pone.0342697.ref004","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"A Mantovani","year":"2018","journal-title":"Diabetes Care"},{"issue":"22","key":"pone.0342697.ref005","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"ME Rinella","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"pone.0342697.ref006","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"G Targher","year":"2016","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0342697.ref007","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"ZM Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"12","key":"pone.0342697.ref008","article-title":"2019 global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"MH Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"pone.0342697.ref009","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"JV Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10258","key":"pone.0342697.ref010","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"pone.0342697.ref011","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3390\/jcm10091877","article-title":"Performance of fatty liver index in identifying non-alcoholic fatty liver disease in population studies. a meta-analysis","volume":"10","author":"M Castellana","year":"2021","journal-title":"J Clin Med"},{"issue":"10258","key":"pone.0342697.ref012","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"key":"pone.0342697.ref013","doi-asserted-by":"crossref","DOI":"10.1201\/b16018","volume-title":"Bayesian data analysis","author":"A Gelman","year":"2013","edition":"3"},{"key":"pone.0342697.ref014","author":"OB Ahmad","year":"2001"},{"issue":"10258","key":"pone.0342697.ref015","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(20)30750-9","article-title":"Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"GBD 2019 Universal Health Coverage Collaborators","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"pone.0342697.ref016","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1002\/sim.6248","article-title":"A Bayesian generalized age-period-cohort power model for cancer projections","volume":"33","author":"V J\u00fcrgens","year":"2014","journal-title":"Stat Med"},{"issue":"10159","key":"pone.0342697.ref017","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"22","key":"pone.0342697.ref018","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1001\/jama.2016.13645","article-title":"US county-level trends in mortality rates for major causes of death, 1980-2014","volume":"316","author":"L Dwyer-Lindgren","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"pone.0342697.ref019","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"ZM Younossi","year":"2020","journal-title":"Gut"},{"issue":"1","key":"pone.0342697.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2007.02.009","article-title":"Epidemiology and natural history of NAFLD and NASH","volume":"11","author":"JP Ong","year":"2007","journal-title":"Clin Liver Dis"},{"issue":"6","key":"pone.0342697.ref021","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","author":"S Stender","year":"2017","journal-title":"Nat Genet"},{"issue":"10113","key":"pone.0342697.ref022","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults","volume":"390","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"pone.0342697.ref023","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3350\/cmh.2016.0089","article-title":"The use of immunosuppression in autoimmune hepatitis: A current literature review","volume":"23","author":"A Cropley","year":"2017","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"pone.0342697.ref024","first-page":"61","article-title":"Obesity in menopause - our negligence or an unfortunate inevitability?","volume":"16","author":"J Kozakowski","year":"2017","journal-title":"Prz Menopauzalny"},{"issue":"1","key":"pone.0342697.ref025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12960-024-00940-x","article-title":"Global strategy on human resources for health: workforce 2030-a five-year check-in","volume":"22","author":"M McIsaac","year":"2024","journal-title":"Hum Resour Health"},{"issue":"9985","key":"pone.0342697.ref026","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/S0140-6736(14)61745-1","article-title":"Smart food policies for obesity prevention","volume":"385","author":"C Hawkes","year":"2015","journal-title":"Lancet"},{"key":"pone.0342697.ref027","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Y-L Liu","year":"2014","journal-title":"Nat Commun"},{"issue":"8","key":"pone.0342697.ref028","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/oxfordjournals.aje.a117069","article-title":"Invited commentary: ecologic studies--biases, misconceptions, and counterexamples","volume":"139","author":"S Greenland","year":"1994","journal-title":"Am J Epidemiol"},{"issue":"1","key":"pone.0342697.ref029","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"ME Rinella","year":"2024","journal-title":"Ann Hepatol"},{"issue":"2","key":"pone.0342697.ref030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?","volume":"68","author":"A Lonardo","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0342697.ref031","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"PJ Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"pone.0342697.ref032","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study","volume":"67","author":"AM Allen","year":"2018","journal-title":"Hepatology"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:22:37Z","timestamp":1772648557000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342697"}},"subtitle":[],"editor":[{"given":"Tiejun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342697","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}